BioNTech to channel COVID-19 profits toward developing new Malaria and TB shots in Africa

AFRICA – BioNTech, a Covid-19 vaccine pioneer has said it will invest some of its profits from the Covid-19 vaccine it markets with Pfizer Inc. into developing shots for malaria and tuberculosis in Africa. This is part of the German based biotechnology giant plan to establish a large production hub for innovative medicines on the continent. The firm plans to build a factory in Africa and develop a manufacturing network with local partners to transfer its technology based on messenger RNA, a genetic molecule, to a continent that has suffered…

Read More

Pfizer/BioNTech strike COVID-19 vaccine manufacturing deal with Biovac South Africa

SOUTH AFRICA – Pfizer Inc and BioNTech have entered into a deal with South Africa’s Biovac Institute to process and distribute over 100 million doses a year of their COVID-19 vaccine for the African Union starting 2022. Biovac, a public-private partnership focused on vaccine production, will receive COVID-19 vaccine drug substance made in plants in Europe, and will begin so-called fill-finish operations, the last stage of drug manufacturing and packaging, in 2022. The deal, under which the Cape Town-based Biovac Institute will fill vials of the Pfizer/BioNTech vaccine and ready…

Read More

National institute of health believe mRNA vaccines can protect patients against COVID-19 for longer periods

US – According to the new study published in the Nature journal, people who received mRNA vaccines of Pfizer-BioNTech are more likely to be protected form the corona virus for longer periods than it was previously anticipated. The study was conducted by a National institute of Health supported research team led by Jackson Turner, Jane O’Halloran, Rachel Presti, and Ali Ellebedy at Washington University School of Medicine, St. Louis. Based on the research team findings, the immune systems of individuals who received Pfizer-BioNTech vaccines exhibited robustness and persistence that the…

Read More

Pfizer and BioNTech seek approval for a third jab meant to improve the vaccine’s efficacy

WORLD – Pfizer and BioNtech are planning to have their third COVID-19 vaccine jab approved for use in the US and the European Union. Both companies strongly believe that the third jab will improve the vaccines efficacy rate and could potentially boost individuals against contagious variants. The move comes amid fears that the delta variant is behind the latest outbreaks in Asia and Africa and rising cases in Europe and the US which scientists currently have discovered how it evades the human immune system. According to a new study published…

Read More

‘Mix match’ COVID-19 vaccine approach under consideration following promising results

UK – The UK based Com-Cov study, involving trial usage of two different COVID-19 vaccines, that began early this year has brought back positive with data showing it is still potent against protecting an individual from the virus. This is the ever first trial in the world to evaluate the effects of using different COVID-19 vaccines for the first and second dose within a two-dose vaccination regimen. It is designed to monitor the impact of the different dosing regimens on immune responses and is being run by the National Immunization…

Read More

Siemens, BioNTech expand collaboration for global vaccine production as the fight against the pandemic intensifies

WORLD – German biotechnology company BioNTech SE and Siemens, a German tech company have intensified their collaboration for the rapid expansion and creation of production capacity for the Covid-19 vaccine. BioNTech is aiming to establish a new production site for the production of COVID-19 vaccines in Marburg and Singapore as it has already converted an existing plant into a vaccine production facility through the help of Siemens. Under this cooperation, Siemens will provide the latest automation and digitalization technologies for BioNTech production sites, such as design, simulation, and engineering software…

Read More

BioNTech’s BNT111 phase 2 clinical trial makes progress as patient with advanced Melanoma treated

GERMANY – BioNTech, a German pharmaceutical company, has announced that the first patient has been treated in its BNT111 phase 2 cancer medication trial. Currently, the study is evaluating the Company’s therapeutic cancer vaccine candidate BNT111 in combination with Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody, in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. Melanoma is a type of skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control or can be refereed to hyperpigmentation. BNT111…

Read More

Serum Institute to introduce Novavax’s vaccine in India by September

INDIA – The Indian government through the Serum Institute of India (SII) is planning to introduce an Indian version of Covavax originally formulated by a US based biotech company, Novavax Inc. Clinical trials are underway in India and the vaccine is likely to hit the market under the name Covavax by September this year though clinical trials on children are expected to kick-off from July. The vaccine is among the first to have undergone phase 3 clinical trials at a time when new Covid-19 variants of concern such as the…

Read More